AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials

blonca9
Jul 23
1 min read

She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with drug design, but also safety and patient recruitment.

Recent Posts

See All

After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

Checking in on the progress of CAR-T for autoimmune conditions with the CEO of Kyverna - the company's first (and first for the field) registration intended trial will read in the first half of 2026

AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight